Moreover, the inhibition of CD36, either genetically or with function-blocking antibodies, was shown to be even more efficacious when it is combined with anti-PD-1 antibodies via further eliciting anti-tumor immunity in immunocompetent mice, thereby adding another layer of therapeutic value to targeting CD36 in cancer [56,81]. Here, CD36 is linked to cancer.